HOME >> BIOLOGY >> NEWS
JCI table of contents, February 2, 2004

y, Kevan Herald from the Naomi Berrie Diabetes Center at Columbia University, New York, comments that "these new findings concerning the responses of normal individuals and patients with T1DM to autoantigens shed light on the differences in immune responses between these two groups and the mechanisms of pathogenesis of the disease. The findings suggest ways in which regulation of the autoimmune response occur and offer approaches to immune modulation and ultimately tolerance, the immunologist's "Holy Grail."

TITLE: Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health

AUTHOR CONTACT:
Mark Peakman
King's College London, London, United Kingdom.
Phone: 44-207-955-4656
Fax: 44-207-955-8894
E-mail: mark.peakman@kcl.ac.uk

View the PDF of this article at: https://www.the-jci.org/press/19585.pdf

ACCOMPANYING COMMENTARY: Achieving antigen-specific immune regulation

AUTHOR CONTACT:
Kevan C. Herold
Naomi Berrie Diabetes Center, Columbia University, New York, New York, USA.
Phone: (212) 305-3171
Fax: (212) 851-5493
E-mail: kh318@columbia.edu

View the PDF of this commentary at: https://www.the-jci.org/press/20963.pdf


2. Skin regeneration not isolated to epidermal stem cells

The outermost layer of the skin the epidermis is a rapidly renewing tissue and relies on the regenerative capacity of keratinocytes. Skin grafts using human cultured epidermal cells have been successful in treating patients with severe skin wounds. The notion that the ability to regenerate functional epidermal tissue is an exclusive property of epidermal stem cells is a general assumption in the stem cell biology field
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
2-Feb-2004


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. JCI table of contents September 15, 2004
4. JCI table of contents: 1 September, 2004
5. Anti-cancer compound in vegetables found to block late-stage breast-cancer cell growth
6. JCI table of contents, 16 August, 2004
7. JCI table of contents, 2 August, 2004
8. When male fish hum, females swim in, thanks to hormones, adaptable hearing
9. JCI table of contents, 1 July 2004
10. Search and destroy protein turns tables on HIV
11. JCI table of contents, 15 June 2004

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2017)... 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or ... individuals. (PRNewsFoto/Dermalog Identification Systems) ... "Face Matching" is the fastest software for biometric Face Matching on the market. ...
(Date:3/7/2017)... 2017   HireVue , the leading provider of ... the best talent, faster, today announced the additions of ... and Diana Kucer as Chief Marketing Officer ... team poised to drive continued growth in the company,s ... of record bookings in 2017. "Companies worldwide ...
(Date:3/2/2017)... 2, 2017 Who risk to be deprived ... the full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE ... FIELD? Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... March 24, 2017   Sienna Biopharmaceuticals, Inc. , ... today announced that Richard Peterson will join ... Peterson, who brings more than two decades ... , who is retiring at the end of April ... capacity. Peterson joins Sienna from Novan, Inc., where he ...
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics ... DCVax® personalized immune therapies for solid tumor cancers, ... $7.5 million financing it announced last Friday, March ... to several institutional investors securities totaling 28,843,692 shares, ... share, and 10,000,000 shares of Class C Warrants ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ... strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 ...
Breaking Biology Technology:
Cached News: